Invesco Dorsey Wright Healthcare Momentum ETF

Goldman Sachs and other brokers upgrade BrightSpring Health Services rating; quarterly earnings beat expectations with institutional buying

Tango Therapeutics 12-Month Average Price Target Raised to $36.91

Tango Therapeutics Plans $500 Million Common Stock Offering

Tango Therapeutics Announces 92% ORR for Vopimetostat Combination in Pancreatic Cancer, to Advance to Phase III Trial

Geode Capital Increases Stake in Celcuity by 8.4% to $82.9M as Insiders Sell

Moody's Upgrades Tenet Healthcare Corporate Family Rating to Ba2, Stable Outlook

Tenet Healthcare Stock Dips Short-Term but Deemed Undervalued by Simply Wall St

KKR Phoenix Aggregator Sells ~14.67M Shares of BrightSpring for $858M

BrightSpring Health Services Insiders Sell Over $19 Million in Stock on June 5

Guggenheim Maintains Buy Rating on Ionis Pharmaceuticals with $106 Target Price

Ionis Pharmaceuticals Outlines Growth Strategy: Q1 Sales Surge, Multiple New Drugs Approving Soon

Ionis to present new data on olezarsen for severe hypertriglyceridemia at three major medical meetings

Celcuity Launches $400 Million Senior Convertible Notes Offering to Repay Loans and Fund Working Capital

Axsome Therapeutics Director Mark Coleman Sells 17,537 Shares for ~$4.06 Million

Celcuity: gedatolisib combination shows superior Phase 3 results in PIK3CA breast cancer, plans supplemental NDA submission to FDA

Multiple Investment Firms Issue or Maintain Buy/Sell Ratings on Praxis Precision Medicines (PRAX)

Juno Therapeutics CEO Martin Rosbrat Sells 9,500 Common Shares

Praxis Precision Medicines: Vormatrigine Epilepsy Trial Fails, POWER2 Enrollment Paused

Unity Biotech CEO Martin A. Rothblatt Sells 9,500 Shares After Exercising Options

Ionis Announces Positive Phase 3 Data for Bepirovirsen, Showing 19% Functional Cure Rate in Hepatitis B

CCSC Tech

Youlife

Core AI

Regentis Biomaterials

Epsium Enterprise

Autozi Internet Tech Global

Leslies

Mega Matrix

eLong Power

Smart Logistics Global

INSM

LABU

ARKG

Insmed shareholders approved the election of Elizabeth McKee Anderson and Clarissa Desjardins as directors, endorsed the 2025 executive compensation package, and ratified Ernst & Young as the independent auditor for 2026. The latest analyst rating for INSM stock is a Buy with a $185.00 price target, though Spark's AI Analyst rates it as Neutral due to financial challenges despite positive revenue guidance.

Tip Ranks

Insmed

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

VG Health

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

BNY Mellon Innovators ETF

SPDR S&P Biotech

VanEck Biotech ETF

Insmed Shareholders Approve Directors, Executive Pay and Auditor

SBIO

Insmed executives sold shares totaling over $3.2 million. CEO William Lewis sold 13,283 shares for $1.54 million, CFO Sara Bonstein sold 8,272 shares for $961,040, and COO Roger Adsett sold 5,837 shares for $678,142, all to cover tax obligations and broker fees. Post-transactions, Lewis holds 287,902 shares, Bonstein 71,486 shares, and Adsett 100,973 shares.

TradingView

ALPS Medical Breakthrough

iShares Global Healthcare

Insmed Insiders Sold Shares Worth Over $3.2M

Stifel Nicolaus analyst Stephen Willey has maintained a Buy rating on Insmed (INSM) with a price target of $200.00, while the stock closed at $101.35. Willey, who focuses on the Healthcare sector, has an average return of 9.7% and a success rate of 44.65%. Insmed has a Strong Buy consensus with a price target of $207.79, indicating a potential upside of 105.02%. Barclays also supports a Buy rating with a target of $237.00.

iShares US Pharma

Stifel Financial

Disc Medicine

Incyte

Barclays

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Stifel Nicolaus Remains a Buy on Insmed (INSM)

Insmed's stock plummeted on Thursday following disappointing results for its new lung medication, Brinsupri, which fell short of high investor expectations but surpassed analyst predictions. The company's shares experienced a sharp decline in response to this news. Despite this setback, analysts continue to express optimism for the future success of Insmed and its product launches.

Unusual Whales

Proshares UltraShort Nasdaq Biotech

Insmed Tanks On Its Most Important Launch; Why Analysts Remain Bullish

Barclays analyst Eliana Merle has reaffirmed a Buy rating on Insmed (INSM) with a price target of $237.00. Merle, a 3-star analyst with a 41.22% success rate, focuses on the Healthcare sector. Additionally, TD Cowen also maintained a Buy rating on Insmed, setting a price target of $243.00.

Alnylam Pharma

Bridgebio Pharma

BioMarin Pharma

Barclays Reaffirms Their Buy Rating on Insmed (INSM)

TRVI

PILL

Equities researchers at HC Wainwright have lowered their FY2030 earnings estimates for Trevi Therapeutics (NASDAQ:TRVI) from $0.79 to $0.70 per share. The firm maintains a "Buy" rating with a target price of $21.00. Other analysts have varied opinions, with Morgan Stanley and Needham & Company also issuing buy ratings but with different price targets. Trevi's stock has seen a recent decline of 2.7%, opening at $14.26, and has a market cap of $1.83 billion. The company focuses on developing non-opioid therapies for pain management.

Market Beat

Trevi Therapeutics

Direxion Pharma & Medical Bull 3X

Morgan Stanley

Alliance HC

REPUBLIC HC

Hancock Whitney

Nano Labs

Weis Markets

Carl Zeiss Meditec AG

NEUBERGER BERMAN REAL ES-W/I

Landbridge Co LLC

Chemours

New England Real Asso

Jewett-Cameron

TJGC

D. BORAL ARC ACQUISITION I CORP. C/WTS 23/07/2030(TO PUR COM)

D Boral ARC Acquisition I

D Boral ARC Acquisition I - Unit

CHINA EB LTD

Arcadian Asset

SC ASSETS HLDGS - D

Rit Capital Partners PLC

Hennessy Capital Investment Corp VII

Hennessy Capital Investment Corp VII - Unit

Virtus Investment

Artisan Partners Asset Management 

VGI Partners Global Investments Ltd.

Kennedy-Wilson

Annaly Capital Mgmt

Sun Capital Management Corp.

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Hancock Whitney Pref Share HWCPZ 6.25 06/15/60

China Everbright Water

EB GRAND CHINA

ANNALY CAPITAL MANAGEMENT INC 6.95% FXD FLTG CUM RED PFD SR F 30/09/22

ANNALY CAPITAL MANAGEMENT INC 8.875 CUM PREF SER J

ANNALY CAPITAL MANAGEMENT INC 6.750% FXD TO FTG RATE CUM RED PRF SR I

ANNALY CAPITAL MANAGEMENT INC 6.50 CUM RED PFD STK FIX FLT SER G USD25

Research Analysts Set Expectations for TRVI FY2030 Earnings

Insmed Incorporated reported its first-quarter 2026 financial results, with total revenues of $306 million. BRINSUPRI revenues reached $207.9 million, a 44% increase from Q4 2025, while ARIKAYCE revenues were $98.1 million, up 6% from Q1 2025. The company reiterated its revenue guidance for BRINSUPRI and ARIKAYCE for 2026. Insmed also announced positive results from the Phase 3b ENCORE study of ARIKAYCE and initiated the Phase 3 PALM-PAH study for TPIP. The company is focused on expanding its product offerings and improving patient outcomes.

prnewswire

07:00 ETInsmed Reports First-Quarter 2026 Financial Results and Provides Business Update

Insmed, Inc. (NASDAQ:INSM) experienced a significant increase in short interest, rising 37.0% in March to 13,756,534 shares. Currently, 6.6% of its shares are sold short, with a days-to-cover ratio of 4.7 days based on an average daily volume of 2,950,831 shares. The stock traded down to $146.74, with a market cap of $31.67 billion. Insmed reported a quarterly EPS of ($1.54), missing estimates, and a revenue of $263.84 million, up 152.6% year-over-year. Insider selling activity was noted, with CFO and CEO selling shares recently.

Insmed, Inc. (NASDAQ:INSM) Short Interest Update

Insmed Incorporated has halted its hidradenitis suppurativa program after the Phase 2b CEDAR study for brensocatib failed to meet primary and secondary efficacy endpoints. The study showed no efficacy, with the placebo outperforming treatment arms. Analysts noted predictable outcomes due to high placebo response rates and low investor expectations. Despite the setback, Insmed's focus shifts to Brinsupri and Arikayce, with analysts maintaining a Buy rating and positive price targets for the stock, which saw a slight increase in premarket trading.

benzinga_article

Insmed Drug Misses Primary Goal, Program Axed

Invesco Dorsey Wright Healthcare Momentum ETF(PTH.US)